Week Ending December 27, 2021

2021 in Review: 10 Important Clinical Advances in Cancer at MSK “In 2021, Memorial Sloan Kettering Cancer Center doctors and scientists continued to make major discoveries that will improve the treatment of cancer. Philanthropic donations provided critical support for much of this research, allowing clinical researchers to pursue innovative ideas and take necessary risks to make breakthrough discoveries.” Experts provide top takeaways from the virtual CHEST Annual Meeting “Healio presents highlights from the virtual CHEST Annual Meeting, which was held Oct. 17 to 20.” Karen L. Kelly, M.D. named IASLC Chief Executive Officer of the International Association for the Study of Lung Cancer “The Board of Directors of the International Association for the Study of Lung Cancer (IASLC) is pleased to announce the appointment of Karen L. Kelly, M.D. to the position of Chief Executive Officer, effective Spring 2022.” When a Lung Cancer Diagnosis Brings About a New Mission “Frank was blessed to be very healthy his whole life. He has been a lifelong avid and competitive runner, cyclist and triathlete, placing in the top of his age group in numerous races including the U.S. Cycling Federation State Master’s Time Trial Cycling Championship. He is also an accomplished portrait and landscape artist.” Top 5 Most-Read Articles in Precision Oncology for 2021 “The most-read articles of 2021 for precision oncology included studies into the role of epigenetics for choosing treatments and the presence of circulating tumor DNA to predict recurrence risk, as well as an FDA approval.” A New Horizon in Cancer Care: Liquid Biopsy “Thanks to innovations in liquid biopsy platforms within the past decade, the oncology world is witnessing the transformation of precision medicine in cancer care. The first FDA approval of a liquid biopsy test was the CellSearchCTC enumeration platform in 2013, which is centered on the detection of circulating tumor cells (CTC) in blood.1” Targeting KRAS mutant lung cancer: light at the end of the tunnel “For decades, KRAS mutant lung adenocarcinomas (LUAD) have been refractory to therapeutic strategies based on personalized medicine owing to the complexity of designing inhibitors to selectively target KRAS and downstream targets with acceptable toxicities. The recent development of selective KRASG12C inhibitors represents a landmark after 40 years of intense research efforts since the identification of KRAS as a human oncogene.” VIDEO: “We’re going to get there”: 50 years after start of ‘War on Cancer,’ hopes persist for more progress “Thursday marked 50 years since President Richard Nixon declared a ‘War on Cancer,’ signing the National Cancer Act into law, groundbreaking legislation which helped kickstart massive advancements in treating the disease.” Reviewing the Year 2021 in Lung Cancer Treatment “Good evening and welcome! Thank you for joining OncLive’s fifth episode of Thoracic Night Live, a program devoted to spotlighting the biggest topics in lung cancer and pivotal studies discussed at medical meetings throughout the year.” Oncology Peer Review On-The-Go: Future Directions in Small Cell Lung Cancer Treatment “The final episode of CancerNetwork’s 4-part series on small cell lung cancer (SCLC) welcomes back Wade Iams, MD, a thoracic medical oncologist at the Vanderbilt University Medical Center. In this conversation, Iams looks to the future of SCLC treatments, touching on topics including extending response durations for patients, emerging therapies for extensive stage SCLC, exciting research on the horizon, and more.”